Top Investor Tuesday — Most Active Private Equity Firms in Pharma/Biotech
November 18, 2015
So far this year, PE investors have completed 76 deals involving companies in the global pharmaceuticals & biotechnology space, according to the PitchBook Platform, marking a drop in activity from the past two years, each of which recorded at least 100 deals. To no surprise, add-on transactions in the sector have become more common in the past few years, with the deal type growing from 13% of activity in 2012 to 27.3% in 2014 and 25.5% so far this year. PE shops are targeting increasingly fewer pharma/biotech deals in the U.S. compared to other regions, with the percentage of U.S. transactions decreasing steadily from 2012 (53.8%) through this year thus far (45.8%).
Top PE investors in pharma/biotech since 2010 and their deal counts (incl. add-ons):